ABVC BioPharma (ABVC) Competitors $3.00 -0.02 (-0.66%) Closing price 04:00 PM EasternExtended Trading$3.00 +0.00 (+0.17%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ABVC vs. KYTX, EDIT, HUMA, SOPH, ALLO, DBVT, RNAC, LYEL, ACIU, and JBIOShould you be buying ABVC BioPharma stock or one of its competitors? The main competitors of ABVC BioPharma include Kyverna Therapeutics (KYTX), Editas Medicine (EDIT), Humacyte (HUMA), SOPHiA GENETICS (SOPH), Allogene Therapeutics (ALLO), DBV Technologies (DBVT), Cartesian Therapeutics (RNAC), Lyell Immunopharma (LYEL), AC Immune (ACIU), and Jade Biosciences (JBIO). These companies are all part of the "pharmaceutical products" industry. ABVC BioPharma vs. Its Competitors Kyverna Therapeutics Editas Medicine Humacyte SOPHiA GENETICS Allogene Therapeutics DBV Technologies Cartesian Therapeutics Lyell Immunopharma AC Immune Jade Biosciences ABVC BioPharma (NASDAQ:ABVC) and Kyverna Therapeutics (NASDAQ:KYTX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, risk, institutional ownership and dividends. Is ABVC or KYTX more profitable? ABVC BioPharma's return on equity of -46.76% beat Kyverna Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ABVC BioPharmaN/A -46.76% -23.02% Kyverna Therapeutics N/A -64.98%-56.17% Which has higher valuation and earnings, ABVC or KYTX? ABVC BioPharma has higher earnings, but lower revenue than Kyverna Therapeutics. ABVC BioPharma is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioABVC BioPharma$510K138.47-$4.90M-$0.17-17.65Kyverna Therapeutics$7.03M33.96-$127.48M-$3.68-1.50 Do institutionals & insiders believe in ABVC or KYTX? 11.4% of ABVC BioPharma shares are held by institutional investors. Comparatively, 18.1% of Kyverna Therapeutics shares are held by institutional investors. 17.1% of ABVC BioPharma shares are held by company insiders. Comparatively, 22.0% of Kyverna Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media favor ABVC or KYTX? In the previous week, ABVC BioPharma and ABVC BioPharma both had 1 articles in the media. ABVC BioPharma's average media sentiment score of 0.59 beat Kyverna Therapeutics' score of 0.00 indicating that ABVC BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ABVC BioPharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kyverna Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend ABVC or KYTX? Kyverna Therapeutics has a consensus target price of $16.60, indicating a potential upside of 200.72%. Given Kyverna Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kyverna Therapeutics is more favorable than ABVC BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Kyverna Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88 Which has more risk & volatility, ABVC or KYTX? ABVC BioPharma has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500. Comparatively, Kyverna Therapeutics has a beta of 3.72, indicating that its share price is 272% more volatile than the S&P 500. SummaryKyverna Therapeutics beats ABVC BioPharma on 9 of the 15 factors compared between the two stocks. Get ABVC BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ABVC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABVC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABVC vs. The Competition Export to ExcelMetricABVC BioPharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$70.62M$3.30B$6.07B$10.52BDividend YieldN/A2.29%5.68%4.68%P/E Ratio-17.6521.8677.4026.67Price / Sales138.47265.51518.66204.76Price / CashN/A46.3737.8961.26Price / Book50.009.9312.556.55Net Income-$4.90M-$52.59M$3.30B$277.34M7 Day Performance-5.06%5.28%28,056.16%2.41%1 Month Performance10.70%12.55%28,977.33%9.26%1 Year Performance370.59%28.76%35,796.36%32.66% ABVC BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABVCABVC BioPharma0.777 of 5 stars$3.00-0.7%N/A+399.1%$70.62M$510K-17.6530KYTXKyverna Therapeutics2.3583 of 5 stars$6.31-3.2%$16.60+163.1%+28.5%$272.91M$7.03M-1.7196EDITEditas Medicine4.2685 of 5 stars$3.01+0.3%$5.10+69.4%+20.8%$270.66M$32.31M-1.06230Gap UpHUMAHumacyte2.542 of 5 stars$1.70-4.0%$9.29+446.2%-68.5%$269.23M$1.57M-3.78150Analyst ForecastSOPHSOPHiA GENETICS2.7239 of 5 stars$3.96+0.8%$8.00+102.0%+26.6%$267.62M$65.17M-9.00520Short Interest ↓ALLOAllogene Therapeutics2.9882 of 5 stars$1.17flat$8.44+621.7%-49.0%$259.60M$20K-1.05310Positive NewsDBVTDBV Technologies2.4826 of 5 stars$9.35-1.6%$14.75+57.8%+271.3%$256.19M$4.15M-1.9680Positive NewsGap UpRNACCartesian Therapeutics1.5798 of 5 stars$9.81-2.3%$40.00+307.7%-42.5%$255.06M$38.91M-0.1964News CoverageLYELLyell Immunopharma1.2792 of 5 stars$13.18+0.1%$15.00+13.8%-35.7%$253.19M$60K-0.54270ACIUAC Immune2.4541 of 5 stars$2.52-0.4%$10.00+296.8%-10.1%$253.03M$31.02M-4.34140Positive NewsJBIOJade Biosciences2.1401 of 5 stars$7.61-3.9%$16.00+110.2%N/A$248.31MN/A-0.2520 Related Companies and Tools Related Companies Kyverna Therapeutics Competitors Editas Medicine Competitors Humacyte Competitors SOPHiA GENETICS Competitors Allogene Therapeutics Competitors DBV Technologies Competitors Cartesian Therapeutics Competitors Lyell Immunopharma Competitors AC Immune Competitors Jade Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABVC) was last updated on 10/3/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredChina’s message to TrumpPorter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ABVC BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ABVC BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ABVC Stock Alerts